Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haluk Yücel

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Cancers|May 14, 2025
The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2- Breast Cancer: A Multicenter Observational Study from TurkeyHarun Muğlu, Kaan Helvacı, Bahadır Köylü, et al.
Journal of Clinical Medicine|May 4, 2026
A Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Proliferation-Inflammation (TIPI) ScoreErdem Sünger, Harun Muğlu, Mehmet Haluk Yücel, et al.
Pharmaceuticals (Basel, Switzerland)|May 4, 2026
Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-ImmunotherapyMaral Martin Mıldanoğlu, Fatih Kemik, Melisa Eryaşar, et al.
Journal of Clinical Medicine|March 28, 2026
Real-World Outcomes of Neoadjuvant Dual Blockade in HER2-Positive Breast Cancer: The Role of Tumor Biology and pCRAyberk Bayramgil, Mehmet Haluk Yücel, Ezgi Turkoglu, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Cancers|May 14, 2025
The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2- Breast Cancer: A Multicenter Observational Study from TurkeyHarun Muğlu, Kaan Helvacı, Bahadır Köylü, et al.
Journal of Clinical Medicine|May 4, 2026
A Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Proliferation-Inflammation (TIPI) ScoreErdem Sünger, Harun Muğlu, Mehmet Haluk Yücel, et al.
Pharmaceuticals (Basel, Switzerland)|May 4, 2026
Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-ImmunotherapyMaral Martin Mıldanoğlu, Fatih Kemik, Melisa Eryaşar, et al.
Journal of Clinical Medicine|March 28, 2026
Real-World Outcomes of Neoadjuvant Dual Blockade in HER2-Positive Breast Cancer: The Role of Tumor Biology and pCRAyberk Bayramgil, Mehmet Haluk Yücel, Ezgi Turkoglu, et al.
Pageof 2